Skip directly to content

Zavicefta®▼ (ceftazidime and avibactam)

Zavicefta is an antibiotic medicine, launched in the UK in 2017.

It is recognised that certain types of bacteria which make us ill, are becoming resistant to antibiotics making them difficult to treat. Therefore, a range of different antibiotics are available to try and combat this resistance, Zavicefta is one of these.

Zavicefta is a combination of:

  • An existing antibiotic (Ceftazidime)
  • Avibactam, which gives the antibiotic Ceftazidime a better chance of killing the bacteria, which may otherwise be resistant to it

Zavicefta is used to treat adults with:

  • Complicated intra-abdominal infection
  • Complicated urinary tract infection including pylonephritis
  • Hospital acquired pneumonia, including pneumonia acquired whilst on a ventilator
  • Infections due to a particular type of bacteria which are proving difficult to treat

Medical professionals carefully consider a range of factors before recommending which antibiotic to prescribe.

Zavicefta 2g/0.5g is given as an intravenous infusion, usually in hospital. It is only available with a prescription.

If you would like to see the Patient Information Leaflet (PIL) or Summary of Product Characteristics (SPC) for Zavicefta these can be found at the electronic Medicines Compendium (eMC).

 

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See www.mhra.gov.uk/yellowcard for how to report side effects.

Pfizer is unable to provide advice on personal medical matters. Please consult your doctor or other relevant health professionals for specific, health-related advice and support.

PP-ZVA-GBR-0270 / Oct 2017